
[Expand/Collapse all sections]Expand all

This document outlines details of PBS-subsidised burosumab for patients
with X-linked hypophosphataemia (XLH).

XLH and listing dates

XLH is an inherited rare condition that affects bones, muscles, and
teeth due to the excessive loss of phosphate.

Listing dates are:

-   burosumab - 1 November 2022

See Written Authority Required Drugs, for more details.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains links to contact details, item and
restriction codes, the PBS schedule and the Services Australia website.

Related links

Tier 0 technical support - self-sufficiency

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Processing and National Demand Allocation (PaNDA)

Process telephone Authority approval application

                                   

-   Services Australia ABN 90 794 605 008 
